Audit: QRS - SGLT2 Inhibitors for Health & Longevity
Audit conducted on 09/08/2026 15:24 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All gate items, tier lists, protocol cells, monitoring rows, and qualitative items trace to ER lines 404–423, 171–271, 288–388, 445–457, and 502–533. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Benefit in healthy people is unproven” mirrors ER line 560; “bladder cancer signal” and “unknown long-term effects in metabolically healthy adults” carry the ER’s speculative framing. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain contraindications; the type 1 diabetes item keeps “(outside specialist supervision)” from ER line 423. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and Key Interactions both come from ER Key Interactions & Contraindications; nothing is drawn from Benefit-Modifying Factors or Risk-Modifying Factors. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, expert names, or brand names appear; the agent and example-drug names used are all present in the ER for the same facts. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, non-promotional register matching the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified targets in Monitoring paired with plain-language At-A-Glance text. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | All content is declarative; no imperatives or instructions to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Protocol cells describe what is done in practice rather than telling anyone what to do. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrences of “recommended”, “should take”, or equivalent directive phrasing. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to biomarker names and drug classes, where they are unavoidable and match the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate item, tier list, and monitoring cell is a stripped phrase without elaboration. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text search for “you”/”your”: no matches. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional monitoring targets (apoB <80 mg/dL, hs-CRP <0.8 mg/L, HOMA-IR <1.5) address the optimizing reader, not a general patient. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A 14-marker panel with a front-loaded cadence and lifelong dosing is presented without hedging on effort. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content assumes home ketone measurement, DEXA body composition, and standing blood pressure tracking. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Ketogenic eating and extended fasting are surfaced as a contraindication, and “no perceptible subjective benefit” and “Benefit in healthy people is unproven” address the healthy-user case directly. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear; the page title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “Once-daily tablets”, “genital mycotic infections”, “orthostatic hypotension”; the plain “genital yeast infections” appears only in At-A-Glance, where item 7.4 requires plain language and the ER Conclusion uses the same wording. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings, gate headings, tier labels, and column headers match the template byte-for-byte. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template variable is present; the repeating marker_#_* and qualitative_item_# placeholders are expanded to 14 and 7 instances respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The website="evidence_review", website="audit", and website="full_review" spans, the styles, and the footer disclaimer are unmodified. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels (ER lines 447, 450, 452), all 14 biomarker names (ER lines 510–523), and all 7 qualitative labels (ER lines 527–533) are verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Where the ER supplies a bold label, it is reproduced unchanged; the Time-to-effect labels use the ER’s own terms (“heart failure events”, “kidney decline”) from the single prose bullet at ER line 484. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan returns no emoji code points; tiers are conveyed by CSS classes and bold labels. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its minimum permissible form — mitigations, magnitudes, consequences, and mechanistic text are all stripped — and no section is duplicated or extended with additional prose. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:05" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: sglt2_inhibitors_2026-0807-2103_Opus_ER.md at line 4. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0809-1506. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus at line 7. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word without version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 at line 8. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: sglt2_inhibitors_2026-0807-2103_Opus_QRS.html matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values are trimmed and consistently formatted; the added git_user and git_issue values are unquoted and clean. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “SGLT2 Inhibitors for Health & Longevity - Quick Reference Sheet” at line 22. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “SGLT2 Inhibitors for Health & Longevity” at line 417. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0809-1506 → “08/09/2026” at line 421. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5” at line 425. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header contains only the title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all three Conclusion paragraphs (ER lines 556–560) into mechanism, benefit strength, costs, and the healthy-user gap. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Flushing sugar/salt/water → line 556; unusually strong evidence → line 556; yeast infections, muscle loss, dizziness → line 558; unproven benefit in healthy people → line 560. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | “genital yeast infections”, “deaths from heart causes”, “loss of kidney function”; no acronyms and no drug-class nomenclature. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Only qualitative magnitudes (“modest reductions”); no numbers. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All items derive from the “Populations who should avoid this intervention” bullet at ER line 423. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 12 ER contraindications are present, in ER order, with none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Twelve <li> elements at lines 542–553. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s parenthetical explanations (the 3–6% ketoacidosis rate, the definition of critical limb ischemia) are stripped; no dash-led trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Specialist-supervision qualifier, trimester window, per-agent eGFR thresholds, Child-Pugh C, the 95 mmHg threshold, BMI 20 kg/m², and the three-day preoperative window are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER contraindication bullet uses no ranking notation inside parentheses. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Twelve stop_items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All items derive from ER lines 406–422. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 17 interaction bullets are represented; from ER line 421 only “Time-restricted eating” is carried, since ketogenic diets and prolonged fasting are already Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seventeen <li> elements at lines 561–577. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “caution/monitor” verdict, consequence clause, and “Mitigation:” sentence from the ER is stripped; no dash-led trailing clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Each example list is retained but trimmed to representative members (e.g., “(furosemide, hydrochlorothiazide)”, “(rifampicin, carbamazepine)”); none is dropped entirely. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER interaction bullets use no ranking notation inside parentheses. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Seventeen caution_items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from ER Therapeutic Protocol lines 447, 450, and 452. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Agent and dose, timing of the dose, and single versus split dosing are the three executable decisions in the ER Protocol section; the remaining bullets are comparative positions or response predictors. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three or more actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine cells populated; e.g. action_1 “Empagliflozin 10 mg once daily” with the dapagliflozin alternative from ER line 447. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Heart failure events, kidney decline, and blood pressure/weight, all from ER line 484. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order matches the ER Expected Benefits High-tier ordering: heart failure and cardiovascular death, then chronic kidney disease progression, then blood pressure and weight. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Nine cells populated; e.g. time_2 “Years” with the 2–4 week dip and stabilisation by 8 weeks from ER line 484. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet at line 484. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items are the ER’s own benefit headings from lines 175–271. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans populated at lines 521–532, with 6, 4, 3, and 3 items matching the ER tiers exactly. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; every “Magnitude:” line and body paragraph is stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item; the “⚠️ Conflicted” markers on ER headings are also stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers contain items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items are the ER’s own risk headings from lines 292–388. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans populated at lines 589–600, with 4, 4, 5, and 3 items matching the ER tiers exactly. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER heading alone; incidence rate ratios and absolute rates are stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item; the “⚠️ Conflicted” markers on ER headings are also stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers contain items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows map one-to-one onto the biomarker table at ER lines 508–523. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 14 ER biomarkers are present in ER order, with names verbatim and optimal ranges preserved. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 774 reproduces the baseline window, the 4-week recheck, 3- and 6-month panels, the 6–12 month interval, and the interim-check triggers from ER lines 504–506. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative marker list at ER lines 527–533. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 7 ER qualitative markers are present in ER order with their bold labels verbatim. |
Issues 09/08/2026 15:24
Pass rate 100.00%. No issues found.
Issues 09/08/2026 15:15
- 4.5 — Exceeds one A4 page: The sheet renders to roughly three A4 pages: 17 Key Interactions with full parenthetical example lists (lines 560–578), 12 Contraindications (lines 541–554), a 14-row Monitoring table with multi-line targets and rationales (lines 616–769), and 7 multi-line Qualitative Assessment items (lines 781–803) were carried at ER length rather than condensed to the per-section budget.
- 9.2 — Contraindication duplicated as interaction: Line 576 carries “Ketogenic diets, prolonged fasting, and time-restricted eating” as a Key Interaction although ketogenic eating and extended fasting are already listed as a Contraindication at line 551.
Fixes 09/08/2026 15:15
- 9.2 — Duplicate contraindication removed from interactions: The Key Interactions item “Ketogenic diets, prolonged fasting, and time-restricted eating” was reduced to “Time-restricted eating”, since ketogenic eating and extended fasting are already carried in the Contraindications gate.
- 4.5 — Key Interactions condensed: Parenthetical example lists across the 17 interaction items were trimmed to two representative agents each (e.g., renin-angiotensin blockers from “lisinopril, losartan, spironolactone, finerenone” to “lisinopril, spironolactone”), cutting roughly a quarter of the gate’s rendered height.
- 4.5 — Contraindications tightened: Redundant wording was removed from six items (e.g., “Any prior episode of diabetic ketoacidosis” to “Prior diabetic ketoacidosis”, “Child-Pugh Class C” to “Child-Pugh C”), with all thresholds, agent names, and time windows preserved.
- 4.5 — Monitoring table condensed: Eleven rationale cells and two target cells were shortened without loss of fact (e.g., hematocrit and hemoglobin targets switched from “in men / in women” to parenthetical form), and the cadence text was tightened.
- 4.5 — Qualitative Assessment condensed: All seven items had redundant qualifiers removed from their descriptions while their bold ER labels were kept verbatim.